Second Phase III trial of stroke therapy MaxiPost "showed no significant difference in the overall efficacy and safety or tolerability between MaxiPost and placebo," Bristol reports. The first trial similarly failed to show evidence of benefit (1"The Pink Sheet" Jan. 29, p. 22). "We are now in the process of analyzing the data a little further, and we are going to review our options after that"
You may also be interested in...
Bristol-Myers Squibb's Glucophage XR extended-release metformin for type 2 diabetes is getting 35% of its new prescriptions from patients switching off the company's immediate-release Glucophage, Bristol President-Worldwide Medicines Group Richard Lane told a Jan. 24 conference call.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials